Merck Accepts DTC Limits In Deal With States
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm to pay $58 million to settle claims its consumer ads deceived the public on Vioxx safety.
You may also be interested in...
Another Vioxx Settlement, Another Must-Do List For Merck
Merck has settled Vioxx shareholder derivative litigation by agreeing to implement a host of corporate governance changes. Among the new requirements, Merck must run ads in medical journals publicizing its clinical trial registry, post reviews of its compliance procedures, and create two safety committees
Another Vioxx Settlement, Another Must-Do List For Merck
Merck has settled Vioxx shareholder derivative litigation by agreeing to implement a host of corporate governance changes. Among the new requirements, Merck must run ads in medical journals publicizing its clinical trial registry, post reviews of its compliance procedures, and create two safety committees
J&J Faces New Round Of Risperdal Suits With Ghostwriting Claims
Johnson & Johnson has been hit with another wave of Risperdal (risperidone) product liability suits. While previous suits have claimed the antipsychotic caused diabetes, the current batch alleges that the drug induced gynecomastia, or breast enlargement, in boys and young men